Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation

• Published in: Annals of hematology Vol. 92; no. 1; pp. 125 - 127
• Main Authors: Ordemann, R., Stöhlmacher, J., Beuthien-Baumann, B., Platzek, I., van den Hoff, J., Kroschinsky, F., Middeke, J. M., Platzbecker, U., Zietz, C., Bornhäuser, M., Ehninger, G.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01-01-2013; Springer Nature B.V
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carmustine - administration & dosage; Cisplatin - administration & dosage; Combined Modality Therapy; Compassionate Use Trials; Cyclophosphamide - administration & dosage; Cytarabine - administration & dosage; Dexamethasone - administration & dosage; Doxorubicin - administration & dosage; Etoposide - administration & dosage; Hematology; Humans; Immunoconjugates - therapeutic use; Letter to the Editor; Lymphocyte Transfusion; Lymphoma, Large-Cell, Anaplastic - complications; Lymphoma, Large-Cell, Anaplastic - drug therapy; Lymphoma, Large-Cell, Anaplastic - enzymology; Lymphoma, Large-Cell, Anaplastic - surgery; Male; Medicine; Medicine & Public Health; Melphalan - administration & dosage; Molecular Targeted Therapy; Neoplasm Proteins - analysis; Neoplasm Proteins - antagonists & inhibitors; Oncology; Peripheral Blood Stem Cell Transplantation; Prednisone - administration & dosage; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - therapeutic use; Pyridines - therapeutic use; Receptor Protein-Tyrosine Kinases - analysis; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Remission Induction; Respiration, Artificial; Respiratory Insufficiency - etiology; Respiratory Insufficiency - therapy; Transplantation, Homologous; Vincristine - administration & dosage; Crizotinib; Graft Versus Host Disease; Anaplastic Large Cell Lymphoma; Brentuximab Vedotin; Anaplastic Lymphoma Kinase
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-012-1524-0